Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major depressive disorder. The purpose of this study is to determine the effectiveness of fluoxetine in treating adolescents and young adults diagnosed with both major depressive disorder and marijuana dependence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Fluoxetine

Criteria

Inclusion Criteria:

• DSM-IV diagnosis of current marijuana abuse or dependence, confirmed by SCID-SUD

• DSM-IV diagnosis of current major depressive disorder, confirmed by the K-SADS

• Marijuana use of at least two days within the week prior to enrollment

• Demonstrated adequate levels of depressive symptoms within the week prior to enrollment

Exclusion Criteria:

• DSM-IV diagnosis of bipolar disorder, schizoaffective disorder, or schizophrenia

• Hypo or hyperthyroidism

• Significant cardiac, neurological, or kidney impairment

• Liver disease (SGOT, SGPT, or gamma-GTP greater than 3 times the normal level)

• Use of antipsychotic or antidepressant medication in the month prior to enrollment

• DSM-IV dependence on any substance except marijuana or nicotine; alcohol dependence, or history of drug use

• History of significant medication side effects from any SSRI antidepressant

• Pregnant

• Unable to use adequate contraceptive methods for the duration of the study

• Inability to read or understand English